Efficacy of second-line nivolumab after early time to progression on first-line cytotoxic chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)

Authors :: K. Goto
Hibiki Udagawa
T. Ota
Shigeki Umemura
Keisuke Kirita
Kiyotaka Yoh
S. Matsumoto
Seiji Niho
Source :: Annals of Oncology. 29:viii535
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Time to progression
First line
non-small cell lung cancer (NSCLC)
Hematology
Cytotoxic chemotherapy
medicine.disease
Second line
Internal medicine
medicine
In patient
Nivolumab
business

Full Text Access

Tools